Clinical trial data

Psilocybin Dose, Explained: Why More Isn't Better

The single most common way people get into trouble with psilocybin is the dose. Here's how researchers think about it, why mushrooms make it so hard, and why "more" is the wrong instinct.

Short answer

In clinical trials, psilocybin is measured in milligrams of the pure compound, and the most common dose in depression research is 25 mg. Mushrooms are much harder to dose because their potency varies widely by species, batch, and even individual mushroom. Effects don't scale in a straight line: as the dose rises, the experience gets disproportionately more intense, and the odds of fear and confusion go up. Strong doses should only happen with trained, licensed professionals.

Key takeaways

  • Research uses measured synthetic psilocybin. The standard depression trial dose is 25 mg.
  • Mushroom potency varies a lot, so the same weight can mean very different doses.
  • Intensity climbs steeply with dose, and so do anxiety and confusion.
  • Don't chase stronger experiences by stacking more. Higher doses are a job for licensed facilitators and clinicians.

How doses are measured in research

Clinical trials don't use mushrooms. They use pure, synthetic psilocybin in capsules, measured in milligrams, so every participant gets exactly what the protocol says.

SettingTypical doseNotes
Compass Phase 2b depression trial1, 10, or 25 mg25 mg worked; 1 mg served as the control1
Compass Phase 3 trials25 mgOne dose, or two doses a few weeks apart6
Johns Hopkins dose study5 to 30 mg per 70 kgTested increasing doses in healthy volunteers2
Oregon licensed programAverage about 32 mgIn a 2026 study of 346 clients5

These are clinical numbers from supervised settings with screening and trained staff. They're context, not instructions.

Why mushrooms are a dosing nightmare

A milligram of synthetic psilocybin is always a milligram. Mushrooms aren't so consistent. Psilocybin content varies by species, growing conditions, the individual mushroom, the part of the mushroom, and how it's been dried and stored. That's why the weight of what someone ate is a poor predictor of how strong the experience will be, and why so many bad trips start with "I took the same amount as last time."

It's also why Oregon and Colorado's licensed programs require lab testing and label products by psilocybin content.

Why effects don't scale in a straight line

Here's the part most people get wrong. Going up in dose doesn't produce a proportionally bigger version of the same experience. At low doses, people notice mild changes. Across the middle of the range, intensity climbs steeply, and the experience changes in kind, not just degree: the sense of self can dissolve, and time and space stop behaving.

The research backs this up from a few angles:

  • Brain imaging shows the intensity people report tracks how many serotonin 2A receptors psilocin occupies, and occupancy rises quickly across the dose range.4
  • A review that pooled dose data across studies found most dimensions of the experience increase with dose, including anxiety-related ones.3
  • In Johns Hopkins' dose study, the highest dose produced the most intense experiences and also the most fear and anxiety.2

So doubling an amount isn't twice the trip. It can be a different trip, with a much higher chance of panic and confusion.

More is not better

There's a persistent idea that a bigger dose means a bigger breakthrough. The clinical data doesn't support turning that into a habit. In Compass's trials, a second 25 mg dose a few weeks later helped more people respond than a single dose, which points toward repetition at a measured level, not escalation.6

Our position is simple: don't keep increasing the dose looking for a stronger effect. If you're seeking a strong, deep experience, do it with a licensed facilitator or clinician who specializes in psilocybin, in a setting built for it. Licensed programs screen your health and medications, use tested products, and keep a trained person with you for the whole session. Find one in our psilocybin therapist finder.

What about small doses?

Very small, repeated doses, known as microdosing, are a different practice with much weaker evidence. Read microdosing psilocybin: what the evidence shows.

Common questions

What is a heroic dose?

The phrase was popularized by ethnobotanist Terence McKenna to describe a very high dose taken alone in darkness. It's a cultural reference, not a recommendation. Very high doses raise the risk of overwhelming fear, confusion, and dangerous behavior, which is exactly why clinical programs use measured doses and trained monitors.

Why don't you list mushroom doses in grams?

Because a gram of one mushroom can contain several times more psilocybin than a gram of another, and potency also changes with drying and storage. Gram guidance gives a false sense of precision. Licensed programs in Oregon and Colorado test their products and label psilocybin content in milligrams for this reason.

Does body weight matter?

Somewhat. Early Johns Hopkins studies adjusted doses for body weight, while recent large trials use a fixed 25 mg dose for everyone and found that works well across a range of body sizes.

Sources

  1. Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022. doi.org/10.1056/NEJMoa2206443
  2. Griffiths RR, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011. doi.org/10.1007/s00213-011-2358-5
  3. Hirschfeld T, Schmidt TT. Dose-response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology. 2021. doi.org/10.1177/0269881121992676
  4. Madsen MK, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019. doi.org/10.1038/s41386-019-0324-9
  5. Korthuis PT, et al. Safety and mental health outcomes of Oregon state-regulated psilocybin services. JAMA Network Open. 2026. doi.org/10.1001/jamanetworkopen.2026.30608
  6. Compass Pathways. Six month data from second Phase 3 trial confirming rapid and durable profile. July 7, 2026. businesswire.com

This article is for education only and is not medical or legal advice. Psilocybin is a Schedule I substance under U.S. federal law. Talk with a licensed clinician before making decisions about your health. In a crisis, call or text 988.